ReNeuron, a UK-based stem cell research company, announced that it has signed an exclusive license agreement with Fosun Pharma, a Chinese listed pharmaceutical company, for the development, manufacture and commercialisation of ReNeuron’s CTX and hRPC cell therapy programmes in China.
What’s it about

Source link